Business Context and Reporting Period
This Form 8-K reports on events occurring on June 24, 2026, regarding Lucid Diagnostics Inc. (Nasdaq: LUCD). The filing details the results of the Company's Annual Meeting of Stockholders and a subsequent amendment to its Certificate of Incorporation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and capital structure changes rather than financial performance metrics.
Material Changes
- Authorized Share Capital Increase: Stockholders approved an amendment to increase the total number of authorized common shares from 300,000,000 to 400,000,000 (an increase of 100,000,000 shares). The amendment became effective on June 24, 2026.
- Board of Directors Election: Three Class B directors (James L. Cox, M.D., John R. Palumbo, and Ronald M. Sparks) were re-elected for terms expiring at the 2029 annual meeting.
- Independent Auditor Ratification: Stockholders ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors. The document is a procedural report of stockholder votes and corporate amendments.
Investor Verification Checklist
- Verify the effective date of the Certificate of Amendment filed with the Delaware Secretary of State (June 24, 2026).
- Review the Definitive Proxy Statement (Schedule 14A) filed on April 30, 2026, for the full text of the amendment and rationale for the share increase.
- Confirm the voting totals: 84.7% of outstanding shares were present or represented at the meeting.
- Note the significant number of broker non-votes (46,065,680) on director elections, which did not affect the outcome but indicates broker discretion.